MEIP vs MYNA Comparison

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Mynaric AG operates in the communication equipment business sector. The company is engaged in the manufacture and sale of products and projects and the provision of services in the field of laser technology, in particular in the aerospace, telematics, and satellite services sectors. It operates in two segments: Air and Space. The space segment comprises CONDOR terminals, and the Air segment comprises HAWK terminals. The company's product portfolio consists of Optical ground stations, Air-to-ground terminals, Air-to-air terminals, Space terminals, and Custom products and subcomponents. Its applications consist of high-altitude networks, remote eyes, satellite constellations, earth observation satellites, and others. Geographically, its key revenue is derived from the United States.